Ekso Bionics Holdings, Inc. Provides Sales Guidance for the Fourth Quarter and Full Year Ended December 31, 2016
January 09, 2017 at 10:24 am
Share
Ekso Bionics Holdings, Inc. provided sales guidance for the fourth quarter and full year ended December 31, 2016. For the quarter, the company expects to report revenue of over $2.5 million.
For the full year, the company expects to report revenue of over $14.0 million.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.